The JAK2/STAT3 pathway is activated in IPF, and treatment with JSI-124 (a dual inhibitor of JAK2/STAT3) decreases collagen deposition during lung fibrosis (Milara et al., 2018). Here, JAK2 is linked to idiopathic pulmonary fibrosis.